FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Human Metabolome Technologies's FCF Yield % or its related term are showing as below:
TSE:6090'
s FCF Yield % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 6.94
Current: 6.94
During the past 12 years, the highest FCF Yield % of Human Metabolome Technologies was 6.94%. The lowest was 0.00%. And the median was 0.00%.
TSE:6090's FCF Yield % is ranked better than 86.45% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.365
vs TSE:6090: 6.94
Human Metabolome Technologies FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Human Metabolome Technologies FCF Yield % Related Terms
Human Metabolome Technologies FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6090 vs TMO, DHR, IDXX: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a FCF Yield % of 6.94 as of Jul. 12, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Human Metabolome Technologies and its competitors. According to the industry distribution chart, Human Metabolome Technologies ranks #29 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 13.6%.
Is Human Metabolome Technologies' FCF Yield % too high?
Human Metabolome Technologies' current FCF Yield % is 6.94. Based on the distribution chart, Human Metabolome Technologies ranks #29 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #29 out of 214 companies for FCF Yield %. This places Human Metabolome Technologies in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Human Metabolome Technologies and its competitors. Human Metabolome Technologies's current FCF Yield % is 6.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Overvalued. The stock's GF Value™ is 円529.55, compared to a current price of 円598.00 — trading 12.9% above its estimated fair value. The current FCF Yield % is 6.94. Human Metabolome Technologies' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current FCF Yield % is 6.94 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued.
The current stock price of 円598.00 is trading 12.9% above its estimated GF Value™ of 円529.55.
GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.
Key valuation signals for TSE:6090:
FCF Yield %: 6.94
GF Value™: 円529.55 vs. price of 円598.00 (12.9% above fair value)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Human Metabolome Technologies Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
